Tumor cell adhesion as a risk factor for sentinel lymph node metastasis in primary cutaneous melanoma

Journal of Clinical Oncology

Volumn 33, Issue 23, 2015, Pages 2509-2515

  Meves, Alexander ^a   Nikolova, Ekaterina ^a   Heim, Joel B ^a   Squirewell, Edwin J ^a   Cappel, Mark A ^b   Pittelkow, Mark R ^c   Otley, Clark C ^a   Behrendt, Nille ^d   Saunte, Ditte M ^d   Lock Andersen, Jorgen ^d   Schenck, Louis A ^a   Weaver, Amy L ^a   Suman, Vera J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; BETA3 INTEGRIN GENE; CANCER PATIENT; CANCER SIZE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENERAL PATHOLOGICAL PARAMETERS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LAMININ B1 CHAIN GENE; MAJOR CLINICAL STUDY; MALE; MELANOMA METASTASIS; NEXT GENERATION SEQUENCING; ONCOLOGICAL PARAMETERS; P53 GENE; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; TISSUE TYPE PLASMINOGEN ACTIVATOR GENE; TUMOR BIOPSY; TUMOR CELL ADHESION; TUMOR DIFFERENTIATION; TUMOR GENE; VALIDATION STUDY; AGED; CELL ADHESION; CHEMISTRY; GENE EXPRESSION REGULATION; LYMPH NODE; LYMPH NODE METASTASIS; MELANOMA; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SKIN TUMOR; STATISTICAL MODEL;

BETA3 INTEGRIN; ITGB3 PROTEIN, HUMAN; LAMB1 PROTEIN, HUMAN; LAMININ; PLAT PROTEIN, HUMAN; PROTEIN P53; TISSUE PLASMINOGEN ACTIVATOR; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; CELL ADHESION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN BETA3; LAMININ; LOGISTIC MODELS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940370304     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.7002     Document Type: Article

References (56)

1. Morton DL, Thompson JF, Cochran AJ, et al: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307-1317, 2006
2. Morton DL, Thompson JF, Cochran AJ, et al: Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599-609, 2014
3. Wong SL, Balch CM, Hurley P, et al: Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 30:2912-2918, 2012
4. Balch CM, Morton DL, Gershenwald JE, et al: Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 60:872-875, 2009
5. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
6. Han D, Zager JS, Shyr Y, et al: Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 31:4387-4393, 2013
7. Sabel MS, Rice JD, Griffith KA, et al: Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy. Ann Surg Oncol 19:287-293, 2012
8. Sondak VK, Taylor JM, Sabel MS, et al: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11:247-258, 2004
9. Sabel MS: Sentinel lymph node biopsy for thin melanoma-con. J Surg Oncol 106:217-218, 2012
10. Martin P: Wound healing: Aiming for perfect skin regeneration. Science 276:75-81, 1997
11. Brakebusch C, Bouvard D, Stanchi F, et al: Integrins in invasive growth. J Clin Invest 109:999-1006, 2002
12. Desgrosellier JS, Cheresh DA: Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22, 2010
13. Hieken TJ, Farolan M, Ronan SG, et al: Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 63:169-173, 1996
14. Hieken TJ, Ronan SG, Farolan M, et al: Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases. Surgery 118:669-675, 1995
15. Albelda SM, Mette SA, Elder DE, et al: Integrin distribution in malignant melanoma: Association of the β3 subunit with tumor progression. Cancer Res 50:6757-6764, 1990
16. Talantov D, Mazumder A, Yu JX, et al: Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11:7234-7242, 2005
17. Conway C, Mitra A, Jewell R, et al: Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15:6939-6946, 2009
18. Kashani-Sabet M, Rangel J, Torabian S, et al: A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA 106:6268-6272, 2009
19. Mitra A, Conway C, Walker C, et al: Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer 103:1229-1236, 2010
20. Therneau T, Atkinson B, Ripley B: Recursive Partitioning, R package version 4.1-3. Rochester, MN, Mayo Clinic, 2013
21. Ruczinski I, Kooperberg C, LeBlanc M: Logic regression. J Comput Graph Stat 12:475-511, 2003
22. Desgrosellier JS, Barnes LA, Shields DJ, et al: An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 15:1163-1169, 2009
23. Szklarczyk D, Franceschini A, Kuhn M, et al: The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39:D561-D568, 2011
24. Zanivan S, Meves A, Behrendt K, et al: In vivo SILAC-based proteomics reveals phosphoproteome changes during mouse skin carcinogenesis. Cell Rep 3:552-566, 2013
25. Meves A, Stremmel C, Böttcher TR, et al: β1 integrins with individually disrupted cytoplasmic NPxY motifs are embryonic lethal but partially active in epidermis. J Invest Dermatol 133:2722-2731, 2013
26. Böttcher RT, Stremmel C, Meves A, et al: Sorting nexin 17 prevents lysosomal degradation of β1 integrins by binding to the β1-integrin tail. Nat Cell Biol 14:584-592, 2012
27. Meves A, Geiger T, Zanivan S, et al: Beta1 integrin cytoplasmic tyrosines promote skin tumorigenesis independent of their phosphorylation. Proc Natl Acad Sci U S A 108:15213-15218, 2011
28. Jones PH, Watt FM: Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73:713-724, 1993
29. Tumbar T, Guasch G, Greco V, et al: Defining the epithelial stem cell niche in skin. Science 303:359-363, 2004
30. Glusac EJ: The melanoma 'epidemic,' a dermatopathologist's perspective. J Cutan Pathol 38: 264-267, 2011
31. Glusac EJ: The melanoma 'epidemic': Lessons from prostate cancer. J Cutan Pathol 39:17-20, 2012
32. Han D, Yu D, Zhao X, et al: Sentinel node biopsy is indicated for thin melanomas ≥ 0.76 mm. Ann Surg Oncol 19:3335-3342, 2012
33. Karakousis GC, Gimotty PA, Botbyl JD, et al: Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 13:533-541, 2006
34. Kesmodel SB, Karakousis GC, Botbyl JD, et al: Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12:449-458, 2005
35. Ranieri JM, Wagner JD, Wenck S, et al: The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 13:927-932, 2006
36. Kruper LL, Spitz FR, Czerniecki BJ, et al: Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 107:2436-2445, 2006
37. Wagner JD, Gordon MS, Chuang TY, et al: Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89:453-462, 2000
38. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, et al: Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol 134:983-987, 1998
39. Sassen S, Shaw HM, Colman MH, et al: The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: Analysis of 2303 melanoma patients treated at a single center. Ann Surg Oncol 15:630-637, 2008
40. Paek SC, Griffith KA, Johnson TM, et al: The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 109:100-108, 2006
41. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al: Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 36:347-350, 2003
42. Nielsen PS, Spaun E, Riber-Hansen R, et al: Automated quantification of MART1-verified Ki-67 indices: Useful diagnostic aid in melanocytic lesions. Hum Pathol 45:1153-1161, 2014
43. Nguyen CL, McClay EF, Cole DJ, et al: Melanoma thickness and histology predict sentinel lymph node status. Am J Surg 181:8-11, 2001
44. Wong SL, Brady MS, Busam KJ, et al: Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 13:302-309, 2006
45. Taylor RC, Patel A, Panageas KS, et al: Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25:869-875, 2007
46. Yonick DV, Ballo RM, Kahn E, et al: Predictors of positive sentinel lymph node in thin melanoma. Am J Surg 201:324-328, 2011
47. Venna SS, Thummala S, Nosrati M, et al: Analysis of sentinel lymph node positivity in patients with thin primary melanoma. J Am Acad Dermatol 68:560-567, 2013
48. Murali R, Haydu LE, Quinn MJ, et al: Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg 255:128-133, 2012
49. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
50. Hoek KS, Schlegel NC, Brafford P, et al: Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19:290-302, 2006
51. Stefansson S, Lawrence DA: The serpin PAI-1 inhibits cell migration by blocking integrin αvβ 3 binding to vitronectin. Nature 383:441-443, 1996
52. Bao W, Strömblad S: Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J Cell Biol 167:745-756, 2004
53. Muller PA, Caswell PT, Doyle B, et al: Mutant p53 drives invasion by promoting integrin recycling. Cell 139:1327-1341, 2009
54. Sloan EK, Pouliot N, Stanley KL, et al: Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 8:R20, 2006
55. Hsu MY, Shih DT, Meier FE, et al: Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 153:1435-1442, 1998
56. Gerami P, Barnhill RL, Beilfuss BA, et al: Superficial melanocytic neoplasms with pagetoid melanocytosis: A study of interobserver concordance and correlation with FISH. Am J Surg Pathol 34:816-821, 2010